大肝癌的消融治疗
DOI: 10.3969/j.issn.1001-5256.2021.03.002
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:曹飞负责文献检索、撰写及修改论文; 范卫君负责拟定写作思路,指导撰写文章并最后定稿。
Ablation therapy for large hepatocellular carcinoma
-
摘要: 肝癌是我国最常见的恶性肿瘤之一,当单个肿瘤直径大于5 cm时定义为大肝癌。大肝癌具有肿瘤恶性程度高、易出现肿瘤转移和血管浸润等特点,增加了治疗的难度。外科切除是大肝癌首选的治疗方案,但仅有20%~30%的患者符合手术治疗要求。对于不可切除的大肝癌国内外指南推荐经肝动脉化疗栓塞术(TACE)作为治疗方案,TACE可以控制肿瘤进展并延长患者生存时间,但反复多次的TACE治疗疗效有限,且对患者肝功能造成严重损害,单独的TACE治疗已无法满足临床需求。随着肿瘤消融技术如射频、微波和冷冻消融等不断发展,TACE联合肿瘤消融治疗已成为大肝癌治疗中的一个重要治疗手段。然而目前国内外关于大肝癌消融治疗的疗效仍有较多的争议,因此如何选择合适的消融时机,减少消融术后残留,降低消融术后肿瘤的复发,最终使患者生存获益是目前临床和科研仍需继续探讨的难题。针对以上内容,综述并分析了大肝癌消融治疗的现况、困境及未来发展趋势。Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, and when a single tumor is larger than 5 cm in diameter, it is defined as large HCC. Large HCC has the characteristics of high degree of tumor malignancy and high risk of tumor metastasis and vascular invasion, which increases the difficulty of treatment. Surgical resection is the preferred treatment regimen for large HCC, but only 20%-30% of patients are candidates for surgical treatment. Transarterial chemoembolization (TACE) is recommended as the treatment regimen for unresectable large HCC in Chinese and international guidelines. It can control tumor progression and prolong the survival time of patients; however, repeated TACE has limited efficacy and may cause serious damage to liver function, and TACE alone can no longer meet clinical needs. With the development of tumor ablation techniques such as radiofrequency ablation, microwave ablation, and cryoablation, TACE combined with tumor ablation has become an important treatment method for large HCC. However, there are still controversies over the effect of ablation on large HCC, and therefore, how to choose the appropriate ablation time, reduce tumor residue and recurrence after ablation, and finally bring survival benefits to patients remains a difficult problem to be solved in clinical and scientific research. This article reviews the current status, predicaments, and future development trends of ablation therapy for large HCC.
-
Key words:
- Liver Neoplasms /
- Ablation Techniques /
- Chemoembolization, Therapeutic
-
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492 [2] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009 [3] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2 [4] LIM C, MISE Y, SAKAMOTO Y, et al. Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J]. World J Surg, 2014, 38(11): 2910-2918. DOI: 10.1007/s00268-014-2704-y [5] USTA S, KAYAALP C. Tumor diameter for hepatocellular carcinoma: Why should size matter?[J]. J Gastrointest Cancer, 2020, 51(4): 1114-1117. DOI: 10.1007/s12029-020-00483-z [6] LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739. DOI: 10.1016/S0140-6736(02)08649-X [7] LLOVET JM, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology, 2003, 37(2): 429-442. DOI: 10.1053/jhep.2003.50047 [8] MELCHIORRE F, PATELLA F, PESCATORI L, et al. DEB-TACE: A standard review[J]. Future Oncol, 2018, 14(28): 2969-2984. DOI: 10.2217/fon-2018-0136 [9] LENCIONI R, de BAERE T, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116. DOI: 10.1002/hep.28453 [10] YOON HM, KIM JH, KIM EJ, et al. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: Multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort[J]. J Vasc Interv Radiol, 2013, 24(11): 1639-1646. DOI: 10.1016/j.jvir.2013.06.017 [11] JEONG SO, KIM EB, JEONG SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma[J]. Gut Liver, 2017, 11(3): 409-416. DOI: 10.5009/gnl16001 [12] XUE T, LE F, CHEN R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: A large cohort study[J]. Med Oncol, 2015, 32(3): 64. DOI: 10.1007/s12032-015-0504-3 [13] TAKAKI H, YAMAKADO K, URAKI J, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J]. J Vasc Interv Radiol, 2009, 20(2): 217-224. DOI: 10.1016/j.jvir.2008.10.019 [14] PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. DOI: 10.1200/JCO.2012.42.9936 [15] HU H, CHEN GF, YUAN W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358. DOI: 10.1080/02656736.2018.1462536 [16] GIORGIO A, GATTI P, MONTESARCHIO L, et al. Microwave ablation in intermediate hepatocellular carcinoma in cirrhosis: An Italian multicenter prospective study[J]. J Clin Transl Hepatol, 2018, 6(3): 251-257. http://www.ncbi.nlm.nih.gov/pubmed/30271736 [17] HUANG Z, ZUO M, NI J, et al. Assessment in the survival outcome after transarterial chemoembolization combined withcryoablation for hepatocellular carcinoma (diameter > 4 cm) based on the albumin-bilirubingrade and platelet-albumin-bilirubin grade: A preliminary study[J]. Cancer Manag Res, 2020, 12: 1373-1385. DOI: 10.2147/CMAR.S234116 [18] WEI J, CUI W, FAN W, et al. Unresectable hepatocellular carcinoma: Transcatheter arterial chemoembolization combined with microwave ablation vs. combined with cryoablation[J]. Front Oncol, 2020, 10: 1285. DOI: 10.3389/fonc.2020.01285 [19] ZHU C, LIN S, LIANG J, et al. PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma[J]. Cryobiology, 2019, 87: 86-90. DOI: 10.1016/j.cryobiol.2019.01.015 [20] ROSS AE, HURLEY PJ, TRAN PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer[J]. Prostate Cancer Prostatic Dis, 2020, 23(1): 184-193. DOI: 10.1038/s41391-019-0176-8 [21] ZHANG TQ, HUANG ZM, SHEN JX, et al. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819862966. http://www.ncbi.nlm.nih.gov/pubmed/31489030 [22] TOSO C, MENTHA G, KNETEMAN NM, et al. The place of downstaging for hepatocellular carcinoma[J]. J Hepatol, 2010, 52(6): 930-936. DOI: 10.1016/j.jhep.2009.12.032 [23] SHI F, WU M, LIAN SS, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: Long-term outcomes[J]. Radiology, 2019, 293(3): 707-715. DOI: 10.1148/radiol.2019181991 [24] SHI F, LIAN S, MAI Q, et al. Microwave ablation after downstaging of hepatocellular carcinoma: Outcome was similar to tumor within Milan criteria[J]. Eur Radiol, 2020, 30(5): 2454-2462. DOI: 10.1007/s00330-019-06604-y [25] REN H, AN C, LIANG P, et al. Ultrasound-guided percutaneous microwave ablation assisted by athree-dimensional visualization treatment platform combined with transcatheter arterial chemoembolization for a single large hepatocellular carcinoma 5 cm or larger: A preliminary clinical application[J]. Int J Hyperthermia, 2019, 36(1): 44-54. DOI: 10.1080/02656736.2018.1530459 [26] SCHULLIAN P, JOHNSTON EW, PUTZER D, et al. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors[J]. Sci Rep, 2020, 10(1): 1618. DOI: 10.1038/s41598-020-58383-y [27] LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med. 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857 [28] DHANASEKARAN R, NAULT JC, ROBERTS LR, et al. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy[J]. Gastroenterology, 2019, 156(2): 492-509. DOI: 10.1053/j.gastro.2018.11.001 [29] CHEN S, CAO Q, WEN W, et al. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities[J]. Cancer Lett, 2019, 460: 1-9. DOI: 10.1016/j.canlet.2019.114428 [30] ZHU K, HUANG J, LAI L, et al. Medium or large hepatocellular carcinoma: Sorafenib combined with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 288(1): 300-307. DOI: 10.1148/radiol.2018172028 [31] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2 [32] ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6 [33] FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745 [34] CHU KF, DUPUY DE. Thermal ablation of tumours: Biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3): 199-208. DOI: 10.1038/nrc3672 [35] SHI L, CHEN L, WU C, et al. PD-1 Blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22(5): 1173-1184. DOI: 10.1158/1078-0432.CCR-15-1352 [36] NOUSO K, MIYAHARA K, UCHIDA D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7): 1904-1907. DOI: 10.1038/bjc.2013.542 [37] BURKI TK. Hepatic arterial chemotherapy for hepatocellular carcinoma[J]. Lancet Oncol, 2019, 20(6): e301. DOI: 10.1016/S1470-2045(19)30343-2 [38] LYU N, LIN Y, KONG Y, et al. FOXAI: A phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396. http://www.ncbi.nlm.nih.gov/pubmed/28592441 [39] HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250 [40] GOTO Y, HISAKA T, SAKAI H, et al. Salvage surgery for initially unresectable locally advanced hepatocellular carcinoma downstaged by hepatic arterial infusion chemotherapy[J]. Anticancer Res, 2020, 40(8): 4773-4777. DOI: 10.21873/anticanres.14479
本文二维码
计量
- 文章访问数: 738
- HTML全文浏览量: 220
- PDF下载量: 104
- 被引次数: 0